Vaccinia Virus News and Research

RSS

The vaccinia virus is the "live virus" used in the smallpox vaccine. It is a "pox"-type virus related to smallpox. When given to humans as a vaccine, it helps the body to develop immunity to smallpox. The smallpox vaccine does not contain the smallpox virus and it cannot cause smallpox.

What is the impact of heat treatment on monkeypox virus?

In newly released research, investigators determined the inactivation of monkeypox virus (MPXV) by heat treatment.

12 Aug 2022

Scientists conduct comparative analysis of monkeypox virus profilin-like proteins and human profilin proteins

In a new study, researchers explored monkeypox virus proteomics and structural characteristics of the A42R protein, the only MPXV protein in the RCSB PDB (protein data bank) and the only profilin-like protein of poxviruses with known structure.

10 Aug 2022

Drugs with antiviral activity against monkeypox virus

In a recent study posted as an accepted manuscript in the journal Clinical Infectious Diseases, researchers from the University of Oklahoma described three drugs with antiviral activity against the monkeypox virus (MPXV).

2 Aug 2022

What is the prevalence of orthopoxviruses across different populations?

In a new study, researchers assessed the prevalence of orthopoxviruses among the general populations of Bolivia, France, Laos, and Mali.

20 Jul 2022

Pox viruses deliver proteins that directly interfere with the body's innate immune system

Pox viruses are able to get a head start on infecting a host by delivering a package of proteins that directly interferes with the body's innate immune system.

15 Jul 2022

How may the genetic differences observed in the current monkeypox virus outbreak impact immune responses induced by VACV vaccines?

Researchers assessed the impact of the vaccinia virus vaccine on the immune response against the monkeypox virus.

12 Jul 2022

The impact of gene amplification in virus adaptation through intermediate hosts

Researchers assessed the impact of gene amplification on cross-species adaptation.

12 Jul 2022

Vaccination against smallpox efficiently protects against monkeypox infection

In a new study, researchers assessed the existing information regarding monkeypox infections.

6 Jul 2022

Researchers investigate prevention and therapy against monkeypox infection

Researchers reviewed the preventive and therapeutic measures against monkeypox.

4 Jul 2022

Animal study suggests intranasal COVID vaccine delivery more efficient than intramuscular

In a recent study published in the journal PNAS, researchers demonstrated higher comparative efficacy of the intranasal (IN) route of coronavirus disease 2019 (COVID-19) vaccine administration versus intramuscular route in mice.

12 Jun 2022

Efficacy of MVA-CoV2-S vaccination to prevent SARS-CoV-2 cerebral infection and associated damage

Researchers demonstrated that an MVA vector expressing the SARS-CoV-2 spike protein was 100% effective in preventing neuroinvasion and brain damage by SARS-CoV-2 in transgenic mice.

8 Feb 2022

Oral bacteria-based SARS-CoV-2 vaccine platform

In a new study, researchers engineered the bacterial strain, Salmonella, to express differently-sized antigens to serve as vaccine platforms.

5 Jan 2022

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust and long-lived humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both young and aging mice.

8 Sep 2021

Vaccinia-based COVID-19 vaccines confer immunity in hamster model

In a paper recently uploaded to the preprint server bioRxiv* by Kulkarni et al. (August 3, 2021), the potential of vaccinia virus-based vaccines expressing the full-length SARS-CoV-2 spike protein is examined in mice and Syrian hamsters. The findings report that the vaccine generates high titers of neutralizing antibodies with good activity towards SARS-CoV-2 variants of concern.

5 Aug 2021

CDC monitoring over 200 individuals possibly exposed to monkeypox

The United States Centers for Disease Control and Prevention (CDC) is monitoring over 200 people who may have been exposed to the monkeypox virus.

22 Jul 2021

Researchers review environmental risk assessments for recombinant COVID-19 viral vector vaccines

In a recent review, published in the journal Vaccines, researchers in Belgium look at the recombinant viral vector-vaccine candidates that are primarily against SARS-CoV-2 still in development and discuss their features from an environmental risk point of view.

8 Jun 2021

Vaccines delivered via skin may offer better protection against respiratory diseases

Among infectious diseases that have caused pandemics and epidemics, smallpox stands out as a success story. Smallpox vaccination led to the disease's eradication in the twentieth century.

27 Jan 2021

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic.

14 Jan 2021

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

A new study shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.

6 Jan 2021

Disinfectants with "virucidal activity against enveloped viruses" effective against SARS-CoV-2

A recent study demonstrated that two commercially available surface disinfectant formulations and one hand disinfection formulation that claim "virucidal activity against enveloped viruses" are effective in inactivating the SARS-CoV-2 virus. Their study has been published on the preprint server bioRxiv.

11 Nov 2020